Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase...
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
About this item
Full title
Author / Creator
Wallace, Daniel J , Furie, Richard A , Tanaka, Yoshiya , Kalunian, Kenneth C , Mosca, Marta , Petri, Michelle A , Dörner, Thomas , Cardiel, Mario H , Bruce, Ian N , Gomez, Elisa , Carmack, Tara , DeLozier, Amy M , Janes, Jonathan M , Linnik, Matthew D , de Bono, Stephanie , Silk, Maria E and Hoffman, Robert W
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus.
In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patien...
Alternative Titles
Full title
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2076240930
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2076240930
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(18)31363-1
